{"gene":"LATS2","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":2000,"finding":"LATS2 protein localizes to the nucleus in human cells, as determined by immunoblotting of fractionated cell lysates; the gene maps to chromosome 13q11-q12, a region of frequent LOH in cancers.","method":"Cell fractionation and immunoblotting; fluorescence in situ hybridization","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct fractionation experiment, single lab, single method","pmids":["10673337"],"is_preprint":false},{"year":2003,"finding":"Ectopic Lats2 expression inhibits G1/S transition, downregulates cyclin E/CDK2 kinase activity, suppresses tumor formation in athymic nude mice, and requires LATS2 kinase activity and two conserved LATS domains (LCDs) for its growth-suppressive function. During interphase LATS2 is cytoplasmic; during mitosis it localizes to the mitotic apparatus.","method":"Retroviral overexpression in NIH3T3/v-ras cells, cell cycle profiling, kinase activity assay, subcellular localization by immunofluorescence, nude mouse tumor assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (cell cycle assay, CDK2 kinase assay, localization, in vivo tumor suppression, domain-deletion mutants), single lab","pmids":["12853976"],"is_preprint":false},{"year":2004,"finding":"Aurora-A kinase directly phosphorylates LATS2 at Ser83 in vitro and in vivo; LATS2 and Aurora-A transiently interact and co-localize at centrosomes during the cell cycle; inhibiting S83 phosphorylation partially perturbs centrosomal localization of LATS2.","method":"In vitro kinase assay with phospho-specific antibody, co-immunoprecipitation, immunofluorescence co-localization","journal":"Genes to cells","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus in vivo phospho-antibody validation and co-IP, single lab with multiple orthogonal methods","pmids":["15147269"],"is_preprint":false},{"year":2004,"finding":"Lats2 overexpression induces apoptosis in lung cancer cells via the intrinsic caspase-9 pathway, accompanied by downregulation of anti-apoptotic proteins BCL-2 and BCL-xL (but not BAX); overexpression of BCL-2 or BCL-xL suppresses Lats2-mediated apoptosis.","method":"Adenoviral overexpression, Annexin V, PARP cleavage, DNA laddering, caspase inhibitor rescue, western blot","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal apoptosis assays plus rescue experiment, single lab","pmids":["15265683"],"is_preprint":false},{"year":2004,"finding":"LATS2 is required for embryonic development and genomic integrity; Lats2-/- mouse embryos show centrosome amplification and defective cytokinesis; Lats2 localizes to centrosomes and its overexpression suppresses centrosome overduplication.","method":"Lats2 knockout mouse, MEF analysis, immunofluorescence for centrosome localization, centrosome amplification assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout phenotype with cellular mechanism, centrosome localization and rescue by overexpression, single lab with multiple orthogonal methods","pmids":["15343267"],"is_preprint":false},{"year":2004,"finding":"LATS2 interacts with the androgen receptor (AR) ligand-binding domain, inhibits androgen-regulated gene expression including PSA, and represses AR NH2-/COOH-terminal interaction; LATS2 and AR co-occupy PSA promoter/enhancer regions.","method":"Co-immunoprecipitation, reporter assay, chromatin immunoprecipitation, endogenous PSA mRNA measurement","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction mapping, ChIP, functional reporter assay, single lab with multiple orthogonal methods","pmids":["15131260"],"is_preprint":false},{"year":2006,"finding":"LATS2 interacts with the LIM protein Ajuba during mitosis; the LATS2-Ajuba complex is required for gamma-tubulin recruitment to centrosomes and proper spindle formation; LATS2 phosphorylates Ajuba during mitosis.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA depletion, immunofluorescence for gamma-tubulin and spindle markers","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus co-IP plus functional siRNA knockdown with spindle phenotype, single lab","pmids":["16413547"],"is_preprint":false},{"year":2007,"finding":"Complete Lats2 knockout in mice causes lethality with nervous system defects; knockout cells show centrosome fragmentation, cytokinesis failure, and accelerated mitotic exit; MOB1 family proteins associate with Lats2 and promote its activation.","method":"Lats2 knockout mouse, MEF phenotypic analysis, co-immunoprecipitation of Lats2-MOB1 interaction, immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with mechanistic follow-up (MOB1 interaction, mitotic marker downregulation), multiple orthogonal methods","pmids":["17478426"],"is_preprint":false},{"year":2008,"finding":"Lats2 mediates cardiac myocyte growth inhibition downstream of Mst1; dominant-negative Lats2 attenuates Mst1-induced apoptosis and inhibition of hypertrophy; cardiac-specific Lats2 transgenic mice show reduced ventricular size, while DN-Lats2 transgenic mice develop hypertrophy.","method":"Adenoviral overexpression, dominant-negative mutant, transgenic mice, phenylalanine incorporation assay, cardiac morphometry","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo genetic manipulation with quantitative cardiac phenotypes, epistasis via dominant negative, replicated across cell and mouse models","pmids":["18927464"],"is_preprint":false},{"year":2009,"finding":"Oncogenic H-Ras activates an ATR-Chk1-mediated stress checkpoint that triggers Lats2 translocation from centrosomes to the nucleus with increased Lats2 protein levels, leading to p53 activation, proapoptotic gene induction, and apoptosis/senescence; cells that escape this checkpoint show reduced Lats2 levels associated with Lats2 promoter hypermethylation.","method":"Oncogenic H-Ras expression, immunofluorescence for subcellular localization, qPCR for gene expression, methylation analysis, cell death and senescence assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization experiment with functional consequence plus epigenetic silencing mechanism, single lab, multiple orthogonal methods","pmids":["19855428"],"is_preprint":false},{"year":2010,"finding":"Lats2 is phosphorylated by Chk1 (predominantly) and Chk2 at S408 in response to UV radiation; phosphorylated Lats2 in turn phosphorylates 14-3-3γ at S59; phosphorylated 14-3-3γ translocates to P-bodies; depletion of Lats2 or 14-3-3γ inhibits UV-induced P-body formation.","method":"In vivo phosphorylation mapping, immunoprecipitation/western blot, siRNA knockdown, immunofluorescence for P-body markers","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — phosphorylation site mapping, co-IP, functional siRNA knockdown with P-body phenotype, single lab with multiple orthogonal methods","pmids":["21118956"],"is_preprint":false},{"year":2010,"finding":"LATS2 mRNA is a direct target of the RNA-binding protein tristetraprolin (TTP); TTP binds AU-rich elements in the LATS2 3'UTR and promotes LATS2 mRNA decay; TTP overexpression reduces LATS2 protein levels, while TTP knockdown stabilizes LATS2 mRNA and suppresses cancer cell proliferation.","method":"RNA electrophoretic mobility shift assay (REMSA), luciferase reporter assay with LATS2 AREs, siRNA knockdown, western blot, proliferation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct RNA-binding demonstrated by REMSA, functional reporter assay, and siRNA rescue, single lab with multiple orthogonal methods","pmids":["20335167"],"is_preprint":false},{"year":2010,"finding":"Lats2 phosphorylates ASPP1 in response to oncogenic stress, driving ASPP1 nuclear translocation; nuclear ASPP1 together with Lats2 directs p53 to proapoptotic promoters and promotes death of polyploid cells; YAP1 disrupts Lats2-ASPP1 binding and antagonizes this tumor-suppressive axis.","method":"Co-immunoprecipitation, in vitro kinase assay (Lats2 phosphorylating ASPP1), immunofluorescence for ASPP1 localization, reporter assay, apoptosis assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus in vivo localization plus functional rescue with YAP1, single lab with multiple methods","pmids":["21041410"],"is_preprint":false},{"year":2010,"finding":"LATS1 and LATS2 interact with HSP90; HSP90 inhibition depletes both kinases via the proteasome, reduces LATS1 catalytic activity, and disrupts downstream YAP phosphorylation; LATS1/2 are bona fide HSP90 client proteins.","method":"Co-immunoprecipitation with HSP90, in vitro kinase assay after HSP90 inhibitor treatment, western blot in cells and clinical specimens","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — co-IP plus kinase activity assay, validated in vivo in clinical samples, single lab","pmids":["20841485"],"is_preprint":false},{"year":2011,"finding":"Angiomotin-family proteins AMOT, AMOTL1, and AMOTL2 activate LATS2 through a conserved domain; AMOTL2 serves as a scaffold binding MST2, LATS2, and YAP; LATS2, AMOTL2, and YAP co-localize at tight junctions, suggesting tight junction clustering triggers LATS2 activation at high cell density.","method":"Co-immunoprecipitation, kinase activation assay, immunofluorescence for tight junction co-localization","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP showing scaffold complex, activation assay, co-localization, single lab with multiple orthogonal methods","pmids":["21832154"],"is_preprint":false},{"year":2011,"finding":"LATS2 cooperates with pRB to silence E2F target genes and promote DREAM complex assembly; LATS2 phosphorylates DYRK1A, which in turn phosphorylates the DREAM subunit LIN52; partial LATS2 knockdown suppresses pRB-induced senescence markers.","method":"shRNA screen, kinase assay (LATS2 phosphorylating DYRK1A; DYRK1A phosphorylating LIN52), DREAM complex ChIP, gene expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assays plus ChIP plus genetic epistasis via shRNA screen, single lab with multiple orthogonal methods","pmids":["21498571"],"is_preprint":false},{"year":2011,"finding":"Aurora A phosphorylates Lats2 at Ser380 during mitosis; S380-phosphorylated Lats2 co-localizes at the central spindle with Aurora B; Lats1 phosphorylates Aurora B; the Aurora A-Lats1/2-Aurora B axis regulates accurate mitotic progression; cells expressing non-phosphorylatable S380A Lats2 show chromosome missegregation and cytokinesis failure.","method":"In vitro kinase assay, phospho-specific antibody, immunocytochemistry, co-immunoprecipitation, mutant expression analysis","journal":"Cell cycle","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus phospho-antibody validation plus functional mutant phenotype, single lab","pmids":["21822051"],"is_preprint":false},{"year":2011,"finding":"LATS2 is a tumor suppressor in malignant mesothelioma; re-expression of LATS2 in MM cells phosphorylates and inactivates YAP, inhibiting MM cell growth.","method":"LATS2 transduction in MM cell lines, western blot for YAP phosphorylation, proliferation assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional rescue with defined mechanistic readout (YAP phosphorylation), validated in multiple MM lines and tumors","pmids":["21245096"],"is_preprint":false},{"year":2011,"finding":"Lats2 kinase interacts with Snail1 and directly phosphorylates Snail1 at Thr203 in the nucleus, promoting Snail1 nuclear retention and stability, enhancing EMT and tumor cell invasion in a Snail1-dependent manner; during TGFβ-induced EMT, Lats2 is activated and Snail1 is phosphorylated at T203.","method":"Live-cell bioluminescence kinome RNAi screen, co-immunoprecipitation, in vitro kinase assay, immunofluorescence, mouse and zebrafish in vivo studies","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with site-specific phosphorylation, validated in multiple model systems (cells, mouse, zebrafish), single lab","pmids":["21952048"],"is_preprint":false},{"year":2013,"finding":"LATS2 inhibits oncogenic Wnt/β-catenin transcription by directly interacting with β-catenin and disrupting the β-catenin/BCL9 interaction, independent of LATS2 kinase activity; LATS2 is present on Wnt target gene promoters.","method":"Co-immunoprecipitation, ChIP, reporter assay, kinase-dead mutant, in vivo tumor model with nocodazole","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP mapping interaction surface, ChIP on Wnt promoters, kinase-dead mutant defining mechanism, single lab with multiple methods","pmids":["24360964"],"is_preprint":false},{"year":2013,"finding":"Lats2 phosphorylates p21/CDKN1A at S146 in response to UV irradiation; this phosphorylation is preceded by Chk1-mediated phosphorylation of Lats2 at Ser835 (which activates Lats2 kinase); Lats2-mediated p21 phosphorylation induces p21 degradation, caspase-3 and -9 activation, and apoptosis.","method":"In vitro kinase assay, phospho-specific antibodies, overexpression/knockdown, caspase activity assay, western blot","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay identifying substrate and phosphorylation site, validated in vivo with functional apoptosis readout, single lab","pmids":["23886938"],"is_preprint":false},{"year":2013,"finding":"At high cell density, active Lats2 inhibits c-Abl tyrosine kinase activity through direct interaction and phosphorylation of c-Abl, reducing phosphorylation of YAP and p73, and suppressing DNA damage-induced apoptosis; Lats2 knockdown restores c-Abl activity and apoptosis in dense cells.","method":"Co-immunoprecipitation, in vitro kinase assay for Lats2-c-Abl interaction, phospho-substrate western blot, siRNA knockdown, apoptosis assay","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus co-IP plus functional knockdown phenotype, single lab with multiple methods","pmids":["23852372"],"is_preprint":false},{"year":2016,"finding":"LATS2 kinase activation requires phosphorylation of both Ser872 (T-loop) and Thr1041 (hydrophobic motif); MST1/2 phosphorylate LATS2 on Thr1041 but not Ser872; MOB1 binding to LATS2 supports both phosphorylation events; a hyperactive LATS2-PIF variant phosphorylates YAP1 and inhibits its transcriptional co-activity dependent on LATS2 kinase activity but independent of MOB1/LATS2 or YAP1/LATS2 complex formation.","method":"Phosphomimetic and phosphoablating LATS2 variants, in vitro kinase assay, MOB1/LATS2 interaction assays, YAP1 transcriptional reporter assay","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-specific mutagenesis combined with kinase assays and reporter assays, multiple orthogonal methods, single lab","pmids":["26898830"],"is_preprint":false},{"year":2016,"finding":"Zyxin acts as a scaffold forming a ternary complex with Lats2 and the E3 ubiquitin ligase Siah2 in response to hypoxia and TGF-β stimuli, facilitating Lats2 ubiquitination and proteasomal degradation, thereby decreasing Hippo signaling and activating YAP.","method":"Co-immunoprecipitation, ubiquitination assay, Lats2 protein stability assay, siRNA knockdown of Zyxin, in vivo xenograft","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ternary complex demonstrated by co-IP, ubiquitination assay establishing mechanism, functional rescue, single lab with multiple methods","pmids":["27030211"],"is_preprint":false},{"year":2016,"finding":"Activated YAP, together with TEAD transcription factors, directly induces transcription of LATS2 (but not LATS1), forming an evolutionarily conserved negative feedback loop; this feedback is functionally relevant as Lats2 deletion in a Sav1-knockout mouse liver model severely enhances YAP-induced tumorigenesis.","method":"ChIP/reporter assay for YAP-TEAD on LATS2 promoter, Lats2-specific knockout in vivo, soft agar assay, Drosophila ortholog validation","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP/reporter assay plus in vivo genetic model plus cross-species validation (Drosophila), multiple labs implicit via cross-species conservation","pmids":["27006470"],"is_preprint":false},{"year":2016,"finding":"LATS2 interacts with the transcription factor SREBP2 (master regulator of cholesterol homeostasis); LATS2 depletion activates SREBP and causes hepatic cholesterol accumulation; liver-specific Lats2 conditional knockout mice develop spontaneous fatty liver disease with constitutive SREBP activation, and show impaired p53 activation and failure to recover from cholesterol-induced damage.","method":"Screen for LATS2-interacting proteins, co-immunoprecipitation, liver-specific conditional knockout mouse, western blot, gene expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — protein interaction screen with co-IP validation plus conditional knockout mouse with metabolic phenotypes, single lab with multiple orthogonal methods","pmids":["27013235"],"is_preprint":false},{"year":2017,"finding":"JCAD interacts with the kinase domain of LATS2 and inhibits LATS2-mediated phosphorylation of YAP, thereby upregulating CCND1 and GLI2 to promote hepatoma cell proliferation.","method":"Co-immunoprecipitation, kinase assay (LATS2 phosphorylating YAP in presence/absence of JCAD), western blot, JCAD overexpression/knockdown","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — co-IP plus in vitro kinase inhibition assay plus functional overexpression/knockdown, single lab with multiple methods","pmids":["28775168"],"is_preprint":false},{"year":2017,"finding":"USP9X deubiquitylates LATS2 and prevents its proteasomal degradation; anaphase-promoting complex/cyclosome (APC/C) interacts with LATS2 but does not regulate its protein levels or activity; USP9X ablation activates YAP/TAZ and enhances oncogenic potential of pancreatic cancer cells.","method":"Tandem affinity purification (TAP), co-immunoprecipitation, ubiquitination assay, USP9X knockdown, protein stability assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — TAP identification followed by co-IP, direct deubiquitination assay, proteasome dependency established, single lab","pmids":["29183995"],"is_preprint":false},{"year":2019,"finding":"YAP1 hyperactivation induces cellular senescence in human ovarian surface epithelial cells; LATS2 is elevated in both YAP1-induced and replicative senescence; deletion of LATS2 in hOSEs prevents senescence and switches YAP-induced senescence to malignant transformation, demonstrating a LATS2-YAP1 negative feedback loop controlling cell fate.","method":"LATS2 siRNA/CRISPR deletion, YAP1 overexpression, senescence assays (SA-β-gal), transformation assays in primary hOSEs","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic deletion with defined fate switch phenotype, multiple functional assays, single lab","pmids":["30755404"],"is_preprint":false},{"year":2020,"finding":"O-GlcNAcylation of LATS2 at Thr436 disrupts its interaction with the MOB1 adaptor protein, preventing MST-to-LATS2 signal relay, suppressing LATS2 kinase activity, and consequently hyperactivating YAP/TAZ in breast cancer cells.","method":"Mass spectrometry identification of O-GlcNAc site, site-directed mutagenesis (T436A), co-immunoprecipitation of MOB1-LATS2 interaction, YAP/TAZ phosphorylation western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — MS-identified modification site with mutagenesis validation, co-IP showing disrupted MOB1 binding, functional pathway readout, single lab","pmids":["32513743"],"is_preprint":false},{"year":2021,"finding":"LATS2 activates mTORC1 in pancreatic β-cells, suppressing autophagy; LATS2 is itself an autophagy substrate; LATS2 deficiency improves β-cell viability, insulin secretion, and β-cell mass under diabetic conditions; genetic and pharmacological mTORC1 inhibition counteracts LATS2-induced β-cell apoptosis.","method":"β-cell-specific Lats2 knockout mice, mTORC1 inhibitor (rapamycin), autophagy flux assay, apoptosis assay, insulin secretion measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional knockout plus pharmacological rescue plus autophagy substrate assay, multiple orthogonal methods","pmids":["34389720"],"is_preprint":false},{"year":2022,"finding":"LATS kinases phosphorylate and inhibit MTF1 (metal-responsive transcription factor 1), attenuating heavy metal response gene transcription; this function is independent of YAP/TAZ; zinc directly binds LATS and inhibits its kinase activity following heavy metal treatment.","method":"In vitro kinase assay (LATS phosphorylating MTF1), zinc binding to LATS, Hippo-deficient cell lines, transcriptional reporter assay, cell viability under metal stress","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus direct zinc-binding assay plus genetic models, single lab with multiple orthogonal methods","pmids":["35027733"],"is_preprint":false},{"year":2024,"finding":"LATS2 forms biomolecular condensates in response to F-actin cytoskeleton reduction, mediated by its proline-rich motif (PRM); these condensates assemble a signalosome with core Hippo pathway components, activating LATS2 and protecting it from FBXL16 E3-ligase-dependent degradation; condensation recruits and inactivates YAP/TAZ; the oncogenic FBXL16 complex blocks LATS2 condensation by binding the PRM, promoting LATS2 degradation.","method":"Live-cell imaging of condensate formation, PRM deletion/mutation, co-immunoprecipitation of FBXL16-LATS2, ubiquitination assay, LATS2 kinase activity and YAP/TAZ phosphorylation assays, tumor progression models","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — condensate formation with domain-mutant validation, E3 ligase interaction and ubiquitination assay, kinase activation and YAP inactivation readouts, multiple orthogonal methods in single study","pmids":["38200110"],"is_preprint":false},{"year":2008,"finding":"Kpm/Lats2 stabilizes YAP2 (through YAP2 phosphorylation at Ser127) and p73 in leukemic cells; Lats2 kinase activity and YAP2 phosphorylation are required for nuclear accumulation of p73, its recruitment to the PUMA promoter, and induction of p21/PUMA expression in response to DNA damage.","method":"Co-expression studies, western blot for p73 stability, chromatin immunoprecipitation for p73 at PUMA promoter, Lats2 knockdown/overexpression, kinase-dead mutant","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus kinase-dead mutant analysis plus co-expression, single lab with multiple methods","pmids":["18565851"],"is_preprint":false}],"current_model":"LATS2 is a serine/threonine kinase (Dbf2-related/AGC family) that forms the catalytic core of the Hippo tumor-suppressor pathway: it is activated by MST1/2-mediated phosphorylation of its hydrophobic motif (Thr1041) and by MOB1 binding (which also supports T-loop Ser872 phosphorylation), assembles into condensates at the plasma membrane in response to cytoskeletal changes to form a YAP/TAZ-inactivating signalosome, phosphorylates YAP and TAZ to restrict their nuclear activity, and additionally phosphorylates diverse substrates including ASPP1 (promoting p53-dependent apoptosis), Snail1 (nuclear retention for EMT), p21/CDKN1A (promoting degradation and apoptosis after UV), c-Abl (inhibiting DNA-damage apoptosis at high density), DYRK1A (linking to DREAM/pRB senescence), and MTF1 (attenuating heavy metal response); its activity and protein levels are regulated by Aurora A phosphorylation (centrosomal localization), Chk1 phosphorylation (UV response), USP9X deubiquitylation (stabilization), Siah2/Zyxin-mediated ubiquitination (degradation), O-GlcNAcylation at Thr436 (MOB1 uncoupling), HSP90 chaperoning, and transcriptional feedback from YAP-TEAD; it also suppresses Wnt signaling by disrupting β-catenin/BCL9 interaction and inhibits SREBP-driven cholesterol metabolism independently of YAP."},"narrative":{"mechanistic_narrative":"LATS2 is a serine/threonine kinase that functions as the catalytic effector of the Hippo tumor-suppressor pathway and as a broader guardian of genomic integrity and cell-fate control [PMID:12853976, PMID:21245096]. Its kinase activity requires dual phosphorylation of the T-loop (Ser872) and the hydrophobic motif (Thr1041), the latter installed by MST1/2, with MOB1 binding supporting both events; this activated kinase phosphorylates and inactivates the transcriptional co-activators YAP/TAZ to restrict their nuclear oncogenic output [PMID:26898830, PMID:21245096]. LATS2 activation is spatially organized: angiomotin-family scaffolds (AMOT/AMOTL1/AMOTL2) cluster LATS2 with MST2 and YAP at tight junctions at high cell density [PMID:21832154], and loss of F-actin drives LATS2 into proline-rich-motif-dependent biomolecular condensates that assemble a Hippo signalosome, activate the kinase, and sequester YAP/TAZ [PMID:38200110]. Beyond YAP/TAZ, LATS2 directly phosphorylates a diverse substrate set to enforce stress responses and growth arrest: ASPP1 (directing p53 to proapoptotic promoters) [PMID:21041410], p21/CDKN1A at Ser146 to promote its degradation and UV-induced apoptosis [PMID:23886938], Snail1 at Thr203 to drive its nuclear retention and EMT [PMID:21952048], c-Abl to suppress DNA-damage apoptosis at high density [PMID:23852372], DYRK1A to assemble the DREAM complex and enforce pRB-dependent senescence [PMID:21498571], and MTF1 to attenuate the heavy-metal response independently of YAP/TAZ [PMID:35027733]. LATS2 also restrains Wnt signaling kinase-independently by disrupting the β-catenin/BCL9 interaction [PMID:24360964] and limits SREBP-driven hepatic cholesterol metabolism [PMID:27013235]. The kinase enforces mitotic fidelity through centrosomal and spindle functions, with knockout causing centrosome amplification and cytokinesis failure [PMID:15343267, PMID:17478426]. Its abundance and activity are tightly tuned by phosphorylation (Aurora-A, Chk1/Chk2), O-GlcNAcylation at Thr436 (which uncouples MOB1), HSP90 chaperoning, USP9X deubiquitylation, and Siah2/Zyxin- and FBXL16-mediated degradation, as well as a YAP-TEAD transcriptional feedback loop [PMID:15147269, PMID:21118956, PMID:32513743, PMID:20841485, PMID:29183995, PMID:27030211, PMID:38200110, PMID:27006470]. Re-expression studies establish LATS2 as a tumor suppressor in malignant mesothelioma and other contexts, frequently silenced by promoter hypermethylation [PMID:21245096, PMID:19855428].","teleology":[{"year":2000,"claim":"Established the basic identity and chromosomal context of LATS2, placing it at a locus of frequent cancer-associated loss and hinting at a tumor-suppressor role.","evidence":"Cell fractionation/immunoblotting and FISH mapping in human cells","pmids":["10673337"],"confidence":"Medium","gaps":["No functional activity demonstrated","Nuclear localization not reconciled with later mitotic/centrosomal findings"]},{"year":2003,"claim":"Demonstrated that LATS2 is a kinase-dependent growth suppressor controlling G1/S transition and tumor formation, defining its core tumor-suppressor function and essential domains.","evidence":"Retroviral overexpression in NIH3T3/v-ras, cell cycle profiling, CDK2 kinase assay, domain-deletion mutants, nude mouse tumor assay","pmids":["12853976"],"confidence":"High","gaps":["Direct substrates not identified","Mechanism linking kinase activity to cyclin E/CDK2 downregulation unresolved"]},{"year":2004,"claim":"Connected LATS2 to mitotic apparatus and centrosome biology, showing it is required for genomic integrity and is regulated by Aurora-A phosphorylation, and that it can trigger intrinsic apoptosis.","evidence":"Lats2 knockout mouse and MEFs, Aurora-A in vitro/in vivo phospho-mapping (Ser83), co-IP, immunofluorescence, adenoviral overexpression with apoptosis assays","pmids":["15343267","15147269","15265683","15131260"],"confidence":"High","gaps":["Substrates at the centrosome not defined","Relationship between AR repression and kinase activity unclear"]},{"year":2006,"claim":"Identified Ajuba as a mitotic LATS2 partner and substrate required for spindle formation, linking LATS2 kinase activity to centrosome maturation.","evidence":"Yeast two-hybrid, co-IP, siRNA depletion, gamma-tubulin/spindle immunofluorescence","pmids":["16413547"],"confidence":"High","gaps":["Ajuba phosphosite not mapped","Functional consequence of phosphorylation on gamma-tubulin recruitment not dissected"]},{"year":2007,"claim":"Established that MOB1-family proteins associate with and activate LATS2, and confirmed in vivo essentiality through knockout lethality with mitotic defects.","evidence":"Lats2 knockout mouse, MEF phenotyping, Lats2-MOB1 co-IP, immunofluorescence","pmids":["17478426"],"confidence":"High","gaps":["MOB1-binding interface on LATS2 not mapped here","Mechanism of activation by MOB1 not yet biochemically defined"]},{"year":2008,"claim":"Placed LATS2 downstream of MST1 in a physiological organ context (heart) and showed it relays growth/apoptosis signals, and linked it to YAP2/p73-dependent DNA-damage gene induction.","evidence":"Cardiac transgenic and dominant-negative mice with morphometry; co-expression, p73 stability, PUMA-promoter ChIP, kinase-dead mutant in leukemic cells","pmids":["18927464","18565851"],"confidence":"High","gaps":["Direct cardiac substrates not identified","Reconciliation of YAP2 stabilization with later YAP-inactivation model not addressed"]},{"year":2009,"claim":"Defined a stress-checkpoint role in which oncogene-induced ATR-Chk1 signaling relocalizes and stabilizes LATS2 to activate p53, and showed promoter hypermethylation as an escape mechanism.","evidence":"Oncogenic H-Ras expression, localization immunofluorescence, qPCR, methylation analysis, death/senescence assays","pmids":["19855428"],"confidence":"High","gaps":["Direct LATS2 substrate driving p53 activation not pinned down here","Quantitative contribution of methylation in human tumors unresolved"]},{"year":2010,"claim":"Expanded the LATS2 substrate/regulator network in stress responses (Chk1/Chk2-LATS2-14-3-3γ P-body axis, ASPP1-p53 proapoptotic targeting) and identified post-transcriptional control by TTP and chaperoning by HSP90.","evidence":"Phosphosite mapping, kinase assays, siRNA, P-body and apoptosis assays; REMSA/luciferase for TTP; co-IP and kinase assay with HSP90 inhibition","pmids":["21118956","21041410","20335167","20841485"],"confidence":"High","gaps":["Hierarchy among competing regulatory inputs not established","In vivo relevance of 14-3-3γ/P-body axis not tested"]},{"year":2011,"claim":"Broadened LATS2 substrate scope into senescence (DYRK1A/DREAM), EMT (Snail1 Thr203), and mitotic accuracy (Aurora-A Ser380 axis), and defined density-dependent activation via angiomotins at tight junctions; confirmed tumor suppression via YAP inactivation in mesothelioma.","evidence":"shRNA screens, in vitro kinase assays with site mapping, ChIP, phospho-antibodies, mutant phenotyping, co-IP, multi-organism EMT models, MM cell rescue","pmids":["21498571","21952048","21822051","21832154","21245096"],"confidence":"High","gaps":["How a single kinase selects among diverse substrates in different contexts unclear","Spatial coordination of mitotic vs Hippo functions unresolved"]},{"year":2013,"claim":"Revealed kinase-independent (Wnt/β-catenin-BCL9) and additional kinase-dependent (p21 Ser146, c-Abl) functions, showing LATS2 integrates UV/DNA-damage and cell-density signals into apoptotic decisions.","evidence":"Co-IP, ChIP, kinase-dead and in vitro kinase assays, knockdown, caspase and apoptosis assays, tumor models","pmids":["24360964","23886938","23852372"],"confidence":"High","gaps":["Switch between proapoptotic and antiapoptotic outputs context-dependence not mechanistically resolved","Structural basis of β-catenin/BCL9 disruption unknown"]},{"year":2016,"claim":"Resolved the biochemical activation logic (Ser872 + Thr1041, MST1/2, MOB1) and uncovered multiple layers of abundance control (Siah2/Zyxin degradation, YAP-TEAD feedback) plus a YAP-independent metabolic role via SREBP2.","evidence":"Phosphomimetic/ablating variants and kinase assays; co-IP and ubiquitination assays; ChIP/reporter and in vivo liver knockouts; interactor screen with conditional knockout metabolic phenotyping","pmids":["26898830","27030211","27006470","27013235"],"confidence":"High","gaps":["Structural model of the active kinase not provided","Crosstalk between metabolic and Hippo outputs not integrated"]},{"year":2017,"claim":"Identified opposing post-translational regulators of LATS2 stability/activity (JCAD inhibition; USP9X deubiquitylation) that tune YAP/TAZ output in cancer.","evidence":"Co-IP, kinase inhibition assays, TAP, ubiquitination and protein-stability assays, knockdown","pmids":["28775168","29183995"],"confidence":"High","gaps":["E3 ligase counteracted by USP9X not fully defined here","JCAD-LATS2 binding interface not mapped structurally"]},{"year":2019,"claim":"Demonstrated that the LATS2-YAP1 negative feedback loop acts as a cell-fate switch, with LATS2 enforcing senescence and its loss permitting YAP-driven transformation.","evidence":"LATS2 siRNA/CRISPR deletion, YAP1 overexpression, SA-β-gal senescence and transformation assays in primary hOSEs","pmids":["30755404"],"confidence":"High","gaps":["Threshold setting the senescence-vs-transformation switch unknown","Downstream senescence effectors not enumerated"]},{"year":2020,"claim":"Showed that O-GlcNAcylation at Thr436 inactivates LATS2 by uncoupling MOB1, providing a metabolic-to-Hippo signaling link that hyperactivates YAP/TAZ.","evidence":"Mass spectrometry site ID, T436A mutagenesis, MOB1-LATS2 co-IP, YAP/TAZ phosphorylation western blot in breast cancer cells","pmids":["32513743"],"confidence":"High","gaps":["O-GlcNAc transferase responsible not defined here","In vivo contribution to tumorigenesis not established"]},{"year":2021,"claim":"Uncovered a LATS2-mTORC1-autophagy axis in pancreatic β-cells, expanding LATS2 function into metabolic-stress-induced apoptosis and revealing it is itself an autophagy substrate.","evidence":"β-cell-specific Lats2 knockout mice, rapamycin rescue, autophagy flux and apoptosis assays, insulin secretion measurement","pmids":["34389720"],"confidence":"High","gaps":["Direct mTORC1-pathway substrate of LATS2 not identified","Relationship of this axis to canonical Hippo signaling unclear"]},{"year":2022,"claim":"Established a YAP/TAZ-independent function in which LATS phosphorylates and inhibits MTF1, with zinc directly binding and inhibiting LATS, positioning LATS2 as a sensor in the heavy-metal stress response.","evidence":"In vitro kinase assay, zinc-binding assay, Hippo-deficient cells, transcriptional reporters, metal-stress viability assays","pmids":["35027733"],"confidence":"High","gaps":["MTF1 phosphosite(s) and LATS2-specific contribution vs LATS1 not delineated","Structural basis of zinc inhibition unknown"]},{"year":2024,"claim":"Defined the spatial/biophysical basis of LATS2 activation by showing F-actin loss drives PRM-dependent condensation into a Hippo signalosome that activates the kinase, sequesters YAP/TAZ, and is antagonized by FBXL16-mediated degradation.","evidence":"Live-cell condensate imaging, PRM mutants, FBXL16-LATS2 co-IP, ubiquitination assay, kinase/YAP-TAZ phosphorylation readouts, tumor models","pmids":["38200110"],"confidence":"High","gaps":["Condensate composition and material properties not fully characterized","How cytoskeletal sensing is transduced to the PRM unresolved"]},{"year":null,"claim":"How LATS2 selects among its many substrates and switches between pro- and anti-apoptotic, kinase-dependent and kinase-independent outputs across cellular contexts remains the central open question.","evidence":"","pmids":[],"confidence":"High","gaps":["No integrated structural model of the active LATS2 kinase with its scaffolds","Quantitative rules governing context-specific substrate choice unknown","In vivo importance of individual non-YAP substrates largely untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,16,18,20,21,22,31,33]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,16,22,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,26,28]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,9,18]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[2,4,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[14,32]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,22,14,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,4,7,16]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,12,20,21,33]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,10,20,31]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[25,30]}],"complexes":["Hippo signalosome (LATS2 condensate)","DREAM complex (functional link)"],"partners":["MOB1","MST1/2","YAP1","AMOTL2","AURKA","USP9X","ZYXIN","SREBP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NRM7","full_name":"Serine/threonine-protein kinase LATS2","aliases":["Kinase phosphorylated during mitosis protein","Large tumor suppressor homolog 2","Serine/threonine-protein kinase kpm","Warts-like kinase"],"length_aa":1088,"mass_kda":120.1,"function":"Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis (PubMed:18158288, PubMed:26437443, PubMed:26598551, PubMed:34404733). The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ (PubMed:26437443, PubMed:26598551, PubMed:34404733). Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration (PubMed:26598551, PubMed:34404733). Also phosphorylates YAP1 in response to cell contact inhibition-driven WWP1 ubiquitination of AMOTL2, which results in LATS2 activation (PubMed:34404733). Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability (PubMed:10871863). Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity (PubMed:12853976). Negative regulator of the androgen receptor (PubMed:15131260). Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities (PubMed:21952048). This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ (PubMed:21952048). Acts as an activator of the NLRP3 inflammasome by mediating phosphorylation of 'Ser-265' of NLRP3 following NLRP3 palmitoylation, promoting NLRP3 activation by NEK7 (PubMed:39173637)","subcellular_location":"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm; Cytoplasm, cytoskeleton, spindle pole; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NRM7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LATS2","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LATS2","total_profiled":1310},"omim":[{"mim_id":"620119","title":"LONG NONCODING RNA CRYBG3","url":"https://www.omim.org/entry/620119"},{"mim_id":"620110","title":"WW AND C2 DOMAINS-CONTAINING PROTEIN 2; WWC2","url":"https://www.omim.org/entry/620110"},{"mim_id":"614041","title":"RB TRANSCRIPTIONAL COREPRESSOR 1; RB1","url":"https://www.omim.org/entry/614041"},{"mim_id":"612044","title":"MICRO RNA 372; MIRN372","url":"https://www.omim.org/entry/612044"},{"mim_id":"611954","title":"MICRO RNA 373; MIR373","url":"https://www.omim.org/entry/611954"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Centriolar satellite","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LATS2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9NRM7","domains":[{"cath_id":"-","chopping":"600-657","consensus_level":"medium","plddt":84.574,"start":600,"end":657},{"cath_id":"1.10.510.10","chopping":"662-825_860-1010_1033-1042","consensus_level":"medium","plddt":86.316,"start":662,"end":1042},{"cath_id":"1.10.8","chopping":"103-140","consensus_level":"medium","plddt":84.2558,"start":103,"end":140}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRM7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRM7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NRM7-F1-predicted_aligned_error_v6.png","plddt_mean":55.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LATS2","jax_strain_url":"https://www.jax.org/strain/search?query=LATS2"},"sequence":{"accession":"Q9NRM7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NRM7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NRM7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NRM7"}},"corpus_meta":[{"pmid":"32106857","id":"PMC_32106857","title":"m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32106857","citation_count":293,"is_preprint":false},{"pmid":"15746036","id":"PMC_15746036","title":"Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15746036","citation_count":263,"is_preprint":false},{"pmid":"26908628","id":"PMC_26908628","title":"Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26908628","citation_count":216,"is_preprint":false},{"pmid":"28644436","id":"PMC_28644436","title":"The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28644436","citation_count":206,"is_preprint":false},{"pmid":"21245096","id":"PMC_21245096","title":"LATS2 is a tumor suppressor gene of malignant mesothelioma.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21245096","citation_count":196,"is_preprint":false},{"pmid":"15343267","id":"PMC_15343267","title":"Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15343267","citation_count":178,"is_preprint":false},{"pmid":"23111389","id":"PMC_23111389","title":"MiR-93 enhances angiogenesis and metastasis by targeting LATS2.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23111389","citation_count":171,"is_preprint":false},{"pmid":"21832154","id":"PMC_21832154","title":"Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.","date":"2011","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/21832154","citation_count":168,"is_preprint":false},{"pmid":"12853976","id":"PMC_12853976","title":"Lats2, a putative tumor suppressor, inhibits G1/S transition.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12853976","citation_count":167,"is_preprint":false},{"pmid":"27195672","id":"PMC_27195672","title":"Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27195672","citation_count":151,"is_preprint":false},{"pmid":"17049657","id":"PMC_17049657","title":"Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma.","date":"2006","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17049657","citation_count":140,"is_preprint":false},{"pmid":"17478426","id":"PMC_17478426","title":"Lats2 is an essential mitotic regulator required for the coordination of cell division.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17478426","citation_count":131,"is_preprint":false},{"pmid":"15147269","id":"PMC_15147269","title":"The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase.","date":"2004","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/15147269","citation_count":121,"is_preprint":false},{"pmid":"19937137","id":"PMC_19937137","title":"miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2.","date":"2009","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/19937137","citation_count":121,"is_preprint":false},{"pmid":"18927464","id":"PMC_18927464","title":"Lats2 is a negative regulator of myocyte size in the heart.","date":"2008","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/18927464","citation_count":115,"is_preprint":false},{"pmid":"21498571","id":"PMC_21498571","title":"A kinase shRNA screen links LATS2 and the pRB tumor suppressor.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21498571","citation_count":108,"is_preprint":false},{"pmid":"10673337","id":"PMC_10673337","title":"Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10673337","citation_count":97,"is_preprint":false},{"pmid":"21952048","id":"PMC_21952048","title":"Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21952048","citation_count":96,"is_preprint":false},{"pmid":"27013235","id":"PMC_27013235","title":"The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27013235","citation_count":95,"is_preprint":false},{"pmid":"30314898","id":"PMC_30314898","title":"Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer.","date":"2018","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30314898","citation_count":94,"is_preprint":false},{"pmid":"21041410","id":"PMC_21041410","title":"The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.","date":"2010","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21041410","citation_count":88,"is_preprint":false},{"pmid":"27030211","id":"PMC_27030211","title":"Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27030211","citation_count":86,"is_preprint":false},{"pmid":"15265683","id":"PMC_15265683","title":"Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L).","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15265683","citation_count":84,"is_preprint":false},{"pmid":"16413547","id":"PMC_16413547","title":"LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis.","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16413547","citation_count":82,"is_preprint":false},{"pmid":"30282996","id":"PMC_30282996","title":"Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30282996","citation_count":76,"is_preprint":false},{"pmid":"35902569","id":"PMC_35902569","title":"m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35902569","citation_count":74,"is_preprint":false},{"pmid":"26934863","id":"PMC_26934863","title":"miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26934863","citation_count":69,"is_preprint":false},{"pmid":"28745315","id":"PMC_28745315","title":"miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28745315","citation_count":67,"is_preprint":false},{"pmid":"28003305","id":"PMC_28003305","title":"Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28003305","citation_count":66,"is_preprint":false},{"pmid":"32054526","id":"PMC_32054526","title":"Exosomal miR-135a derived from human amnion mesenchymal stem cells promotes cutaneous wound healing in rats and fibroblast migration by directly inhibiting LATS2 expression.","date":"2020","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32054526","citation_count":66,"is_preprint":false},{"pmid":"30993599","id":"PMC_30993599","title":"Irisin ameliorates septic cardiomyopathy via inhibiting DRP1-related mitochondrial fission and normalizing the JNK-LATS2 signaling pathway.","date":"2019","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/30993599","citation_count":63,"is_preprint":false},{"pmid":"30037330","id":"PMC_30037330","title":"RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30037330","citation_count":63,"is_preprint":false},{"pmid":"25179841","id":"PMC_25179841","title":"MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25179841","citation_count":63,"is_preprint":false},{"pmid":"30755404","id":"PMC_30755404","title":"YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30755404","citation_count":62,"is_preprint":false},{"pmid":"23977200","id":"PMC_23977200","title":"Lats2 modulates adipocyte proliferation and differentiation via hippo signaling.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23977200","citation_count":62,"is_preprint":false},{"pmid":"20841485","id":"PMC_20841485","title":"Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20841485","citation_count":62,"is_preprint":false},{"pmid":"28775168","id":"PMC_28775168","title":"JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28775168","citation_count":62,"is_preprint":false},{"pmid":"26898830","id":"PMC_26898830","title":"The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26898830","citation_count":61,"is_preprint":false},{"pmid":"23852372","id":"PMC_23852372","title":"The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.","date":"2013","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/23852372","citation_count":59,"is_preprint":false},{"pmid":"31316723","id":"PMC_31316723","title":"miR-25 Promotes Cell Proliferation, Migration, and Invasion of Non-Small-Cell Lung Cancer by Targeting the LATS2/YAP Signaling Pathway.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31316723","citation_count":59,"is_preprint":false},{"pmid":"24360964","id":"PMC_24360964","title":"LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24360964","citation_count":59,"is_preprint":false},{"pmid":"19855428","id":"PMC_19855428","title":"Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19855428","citation_count":59,"is_preprint":false},{"pmid":"31669263","id":"PMC_31669263","title":"The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa.","date":"2019","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31669263","citation_count":58,"is_preprint":false},{"pmid":"21822051","id":"PMC_21822051","title":"The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21822051","citation_count":56,"is_preprint":false},{"pmid":"15131260","id":"PMC_15131260","title":"The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.","date":"2004","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15131260","citation_count":55,"is_preprint":false},{"pmid":"27904778","id":"PMC_27904778","title":"Long non-coding RNA CCAT2 promotes gastric cancer proliferation and invasion by regulating the E-cadherin and LATS2.","date":"2016","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27904778","citation_count":55,"is_preprint":false},{"pmid":"31848340","id":"PMC_31848340","title":"LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31848340","citation_count":54,"is_preprint":false},{"pmid":"35027733","id":"PMC_35027733","title":"The Hippo pathway kinases LATS1 and LATS2 attenuate cellular responses to heavy metals through phosphorylating MTF1.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35027733","citation_count":53,"is_preprint":false},{"pmid":"26360373","id":"PMC_26360373","title":"Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas.","date":"2015","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26360373","citation_count":52,"is_preprint":false},{"pmid":"29183995","id":"PMC_29183995","title":"Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29183995","citation_count":52,"is_preprint":false},{"pmid":"29145896","id":"PMC_29145896","title":"Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.","date":"2017","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29145896","citation_count":52,"is_preprint":false},{"pmid":"32826865","id":"PMC_32826865","title":"LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32826865","citation_count":51,"is_preprint":false},{"pmid":"18565851","id":"PMC_18565851","title":"Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18565851","citation_count":51,"is_preprint":false},{"pmid":"32513743","id":"PMC_32513743","title":"O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32513743","citation_count":48,"is_preprint":false},{"pmid":"20335167","id":"PMC_20335167","title":"Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20335167","citation_count":46,"is_preprint":false},{"pmid":"19008013","id":"PMC_19008013","title":"LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.","date":"2008","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/19008013","citation_count":44,"is_preprint":false},{"pmid":"24735543","id":"PMC_24735543","title":"MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24735543","citation_count":42,"is_preprint":false},{"pmid":"25824045","id":"PMC_25824045","title":"miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25824045","citation_count":40,"is_preprint":false},{"pmid":"31990985","id":"PMC_31990985","title":"The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.","date":"2020","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/31990985","citation_count":39,"is_preprint":false},{"pmid":"30551520","id":"PMC_30551520","title":"LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30551520","citation_count":39,"is_preprint":false},{"pmid":"27006470","id":"PMC_27006470","title":"An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27006470","citation_count":39,"is_preprint":false},{"pmid":"31268774","id":"PMC_31268774","title":"Lats1 and Lats2 are required for ovarian granulosa cell fate maintenance.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31268774","citation_count":38,"is_preprint":false},{"pmid":"23886938","id":"PMC_23886938","title":"Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23886938","citation_count":38,"is_preprint":false},{"pmid":"31097223","id":"PMC_31097223","title":"Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31097223","citation_count":38,"is_preprint":false},{"pmid":"28029651","id":"PMC_28029651","title":"The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28029651","citation_count":38,"is_preprint":false},{"pmid":"25482410","id":"PMC_25482410","title":"Mutation analysis of large tumor suppressor genes LATS1 and LATS2 supports a tumor suppressor role in human cancer.","date":"2014","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/25482410","citation_count":38,"is_preprint":false},{"pmid":"31646568","id":"PMC_31646568","title":"LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31646568","citation_count":37,"is_preprint":false},{"pmid":"25973055","id":"PMC_25973055","title":"LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25973055","citation_count":34,"is_preprint":false},{"pmid":"32157157","id":"PMC_32157157","title":"Long noncoding RNA NEAT1 suppresses hepatocyte proliferation in fulminant hepatic failure through increased recruitment of EZH2 to the LATS2 promoter region and promotion of H3K27me3 methylation.","date":"2020","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32157157","citation_count":32,"is_preprint":false},{"pmid":"29456685","id":"PMC_29456685","title":"miR-372 promotes breast cancer cell proliferation by directly targeting LATS2.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29456685","citation_count":32,"is_preprint":false},{"pmid":"33589592","id":"PMC_33589592","title":"Circular RNA circ_103820 suppresses lung cancer tumorigenesis by sponging miR-200b-3p to release LATS2 and SOCS6.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33589592","citation_count":31,"is_preprint":false},{"pmid":"31004603","id":"PMC_31004603","title":"Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma.","date":"2019","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31004603","citation_count":30,"is_preprint":false},{"pmid":"35642057","id":"PMC_35642057","title":"Metallothionein 2A (MT2A) controls cell proliferation and liver metastasis by controlling the MST1/LATS2/YAP1 signaling pathway in colorectal cancer.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/35642057","citation_count":29,"is_preprint":false},{"pmid":"30981110","id":"PMC_30981110","title":"Anti-tumor effect of LATS2 on liver cancer death: Role of DRP1-mediated mitochondrial division and the Wnt/β-catenin pathway.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30981110","citation_count":29,"is_preprint":false},{"pmid":"21118956","id":"PMC_21118956","title":"A novel Chk1/2-Lats2-14-3-3 signaling pathway regulates P-body formation in response to UV damage.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/21118956","citation_count":29,"is_preprint":false},{"pmid":"34389720","id":"PMC_34389720","title":"The Hippo kinase LATS2 impairs pancreatic β-cell survival in diabetes through the mTORC1-autophagy axis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34389720","citation_count":28,"is_preprint":false},{"pmid":"30896861","id":"PMC_30896861","title":"LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma.","date":"2019","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30896861","citation_count":28,"is_preprint":false},{"pmid":"30456386","id":"PMC_30456386","title":"LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.","date":"2018","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/30456386","citation_count":28,"is_preprint":false},{"pmid":"30481780","id":"PMC_30481780","title":"miR-650 Promotes the Metastasis and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30481780","citation_count":28,"is_preprint":false},{"pmid":"30294667","id":"PMC_30294667","title":"miR-93 Promotes the Growth and Invasion of Prostate Cancer by Upregulating Its Target Genes TGFBR2, ITGB8, and LATS2.","date":"2018","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/30294667","citation_count":28,"is_preprint":false},{"pmid":"28434174","id":"PMC_28434174","title":"Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/28434174","citation_count":25,"is_preprint":false},{"pmid":"25391426","id":"PMC_25391426","title":"Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25391426","citation_count":25,"is_preprint":false},{"pmid":"31239293","id":"PMC_31239293","title":"MicroRNA-302d promotes the proliferation of human pluripotent stem cell-derived cardiomyocytes by inhibiting LATS2 in the Hippo pathway.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31239293","citation_count":25,"is_preprint":false},{"pmid":"32935676","id":"PMC_32935676","title":"miR-497 regulates fatty acid synthesis via LATS2 in bovine mammary epithelial cells.","date":"2020","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/32935676","citation_count":24,"is_preprint":false},{"pmid":"30021349","id":"PMC_30021349","title":"Long non-coding RNA HOTTIP is upregulated in renal cell carcinoma and regulates cell growth and apoptosis by epigenetically silencing of LATS2.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30021349","citation_count":24,"is_preprint":false},{"pmid":"30480622","id":"PMC_30480622","title":"MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2.","date":"2019","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/30480622","citation_count":23,"is_preprint":false},{"pmid":"32654106","id":"PMC_32654106","title":"MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway.","date":"2020","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/32654106","citation_count":22,"is_preprint":false},{"pmid":"25782587","id":"PMC_25782587","title":"LATS2 induced by TNF-alpha and inhibited cell proliferation and invasion by phosphorylating YAP in oral squamous cell carcinoma.","date":"2015","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25782587","citation_count":22,"is_preprint":false},{"pmid":"33268767","id":"PMC_33268767","title":"Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML).","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33268767","citation_count":22,"is_preprint":false},{"pmid":"38200110","id":"PMC_38200110","title":"LATS2 condensates organize signalosomes for Hippo pathway signal transduction.","date":"2024","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38200110","citation_count":21,"is_preprint":false},{"pmid":"32634265","id":"PMC_32634265","title":"The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32634265","citation_count":21,"is_preprint":false},{"pmid":"19238334","id":"PMC_19238334","title":"The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).","date":"2009","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/19238334","citation_count":21,"is_preprint":false},{"pmid":"36860929","id":"PMC_36860929","title":"Platycodin D confers oxaliplatin Resistance in Colorectal Cancer by activating the LATS2/YAP1 axis of the hippo signaling pathway.","date":"2023","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36860929","citation_count":21,"is_preprint":false},{"pmid":"24413153","id":"PMC_24413153","title":"Lats2 is critical for the pluripotency and proper differentiation of stem cells.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/24413153","citation_count":21,"is_preprint":false},{"pmid":"31646563","id":"PMC_31646563","title":"MiR-372-3p promotes tumor progression by targeting LATS2 in colorectal cancer.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31646563","citation_count":20,"is_preprint":false},{"pmid":"34649058","id":"PMC_34649058","title":"Novel insights into the regulation of LATS2 kinase in prehierarchical follicle development via the Hippo pathway in hen ovary.","date":"2021","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/34649058","citation_count":20,"is_preprint":false},{"pmid":"28419554","id":"PMC_28419554","title":"The major miR-31 target genes STK40 and LATS2 and their implications in the regulation of keratinocyte growth and hair differentiation.","date":"2017","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28419554","citation_count":20,"is_preprint":false},{"pmid":"28673012","id":"PMC_28673012","title":"microRNA-605 promotes cell proliferation, migration and invasion in non-small cell lung cancer by directly targeting LATS2.","date":"2017","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28673012","citation_count":20,"is_preprint":false},{"pmid":"34446703","id":"PMC_34446703","title":"MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34446703","citation_count":19,"is_preprint":false},{"pmid":"30771084","id":"PMC_30771084","title":"LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.","date":"2019","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/30771084","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49617,"output_tokens":8567,"usd":0.138678,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18189,"output_tokens":6125,"usd":0.122035,"stage2_stop_reason":"end_turn"},"total_usd":0.260713,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"LATS2 protein localizes to the nucleus in human cells, as determined by immunoblotting of fractionated cell lysates; the gene maps to chromosome 13q11-q12, a region of frequent LOH in cancers.\",\n      \"method\": \"Cell fractionation and immunoblotting; fluorescence in situ hybridization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct fractionation experiment, single lab, single method\",\n      \"pmids\": [\"10673337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ectopic Lats2 expression inhibits G1/S transition, downregulates cyclin E/CDK2 kinase activity, suppresses tumor formation in athymic nude mice, and requires LATS2 kinase activity and two conserved LATS domains (LCDs) for its growth-suppressive function. During interphase LATS2 is cytoplasmic; during mitosis it localizes to the mitotic apparatus.\",\n      \"method\": \"Retroviral overexpression in NIH3T3/v-ras cells, cell cycle profiling, kinase activity assay, subcellular localization by immunofluorescence, nude mouse tumor assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (cell cycle assay, CDK2 kinase assay, localization, in vivo tumor suppression, domain-deletion mutants), single lab\",\n      \"pmids\": [\"12853976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Aurora-A kinase directly phosphorylates LATS2 at Ser83 in vitro and in vivo; LATS2 and Aurora-A transiently interact and co-localize at centrosomes during the cell cycle; inhibiting S83 phosphorylation partially perturbs centrosomal localization of LATS2.\",\n      \"method\": \"In vitro kinase assay with phospho-specific antibody, co-immunoprecipitation, immunofluorescence co-localization\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus in vivo phospho-antibody validation and co-IP, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15147269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Lats2 overexpression induces apoptosis in lung cancer cells via the intrinsic caspase-9 pathway, accompanied by downregulation of anti-apoptotic proteins BCL-2 and BCL-xL (but not BAX); overexpression of BCL-2 or BCL-xL suppresses Lats2-mediated apoptosis.\",\n      \"method\": \"Adenoviral overexpression, Annexin V, PARP cleavage, DNA laddering, caspase inhibitor rescue, western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal apoptosis assays plus rescue experiment, single lab\",\n      \"pmids\": [\"15265683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LATS2 is required for embryonic development and genomic integrity; Lats2-/- mouse embryos show centrosome amplification and defective cytokinesis; Lats2 localizes to centrosomes and its overexpression suppresses centrosome overduplication.\",\n      \"method\": \"Lats2 knockout mouse, MEF analysis, immunofluorescence for centrosome localization, centrosome amplification assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout phenotype with cellular mechanism, centrosome localization and rescue by overexpression, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15343267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LATS2 interacts with the androgen receptor (AR) ligand-binding domain, inhibits androgen-regulated gene expression including PSA, and represses AR NH2-/COOH-terminal interaction; LATS2 and AR co-occupy PSA promoter/enhancer regions.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, chromatin immunoprecipitation, endogenous PSA mRNA measurement\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction mapping, ChIP, functional reporter assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15131260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LATS2 interacts with the LIM protein Ajuba during mitosis; the LATS2-Ajuba complex is required for gamma-tubulin recruitment to centrosomes and proper spindle formation; LATS2 phosphorylates Ajuba during mitosis.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA depletion, immunofluorescence for gamma-tubulin and spindle markers\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus co-IP plus functional siRNA knockdown with spindle phenotype, single lab\",\n      \"pmids\": [\"16413547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Complete Lats2 knockout in mice causes lethality with nervous system defects; knockout cells show centrosome fragmentation, cytokinesis failure, and accelerated mitotic exit; MOB1 family proteins associate with Lats2 and promote its activation.\",\n      \"method\": \"Lats2 knockout mouse, MEF phenotypic analysis, co-immunoprecipitation of Lats2-MOB1 interaction, immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with mechanistic follow-up (MOB1 interaction, mitotic marker downregulation), multiple orthogonal methods\",\n      \"pmids\": [\"17478426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lats2 mediates cardiac myocyte growth inhibition downstream of Mst1; dominant-negative Lats2 attenuates Mst1-induced apoptosis and inhibition of hypertrophy; cardiac-specific Lats2 transgenic mice show reduced ventricular size, while DN-Lats2 transgenic mice develop hypertrophy.\",\n      \"method\": \"Adenoviral overexpression, dominant-negative mutant, transgenic mice, phenylalanine incorporation assay, cardiac morphometry\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo genetic manipulation with quantitative cardiac phenotypes, epistasis via dominant negative, replicated across cell and mouse models\",\n      \"pmids\": [\"18927464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Oncogenic H-Ras activates an ATR-Chk1-mediated stress checkpoint that triggers Lats2 translocation from centrosomes to the nucleus with increased Lats2 protein levels, leading to p53 activation, proapoptotic gene induction, and apoptosis/senescence; cells that escape this checkpoint show reduced Lats2 levels associated with Lats2 promoter hypermethylation.\",\n      \"method\": \"Oncogenic H-Ras expression, immunofluorescence for subcellular localization, qPCR for gene expression, methylation analysis, cell death and senescence assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment with functional consequence plus epigenetic silencing mechanism, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19855428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Lats2 is phosphorylated by Chk1 (predominantly) and Chk2 at S408 in response to UV radiation; phosphorylated Lats2 in turn phosphorylates 14-3-3γ at S59; phosphorylated 14-3-3γ translocates to P-bodies; depletion of Lats2 or 14-3-3γ inhibits UV-induced P-body formation.\",\n      \"method\": \"In vivo phosphorylation mapping, immunoprecipitation/western blot, siRNA knockdown, immunofluorescence for P-body markers\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation site mapping, co-IP, functional siRNA knockdown with P-body phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21118956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LATS2 mRNA is a direct target of the RNA-binding protein tristetraprolin (TTP); TTP binds AU-rich elements in the LATS2 3'UTR and promotes LATS2 mRNA decay; TTP overexpression reduces LATS2 protein levels, while TTP knockdown stabilizes LATS2 mRNA and suppresses cancer cell proliferation.\",\n      \"method\": \"RNA electrophoretic mobility shift assay (REMSA), luciferase reporter assay with LATS2 AREs, siRNA knockdown, western blot, proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct RNA-binding demonstrated by REMSA, functional reporter assay, and siRNA rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"20335167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Lats2 phosphorylates ASPP1 in response to oncogenic stress, driving ASPP1 nuclear translocation; nuclear ASPP1 together with Lats2 directs p53 to proapoptotic promoters and promotes death of polyploid cells; YAP1 disrupts Lats2-ASPP1 binding and antagonizes this tumor-suppressive axis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (Lats2 phosphorylating ASPP1), immunofluorescence for ASPP1 localization, reporter assay, apoptosis assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus in vivo localization plus functional rescue with YAP1, single lab with multiple methods\",\n      \"pmids\": [\"21041410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LATS1 and LATS2 interact with HSP90; HSP90 inhibition depletes both kinases via the proteasome, reduces LATS1 catalytic activity, and disrupts downstream YAP phosphorylation; LATS1/2 are bona fide HSP90 client proteins.\",\n      \"method\": \"Co-immunoprecipitation with HSP90, in vitro kinase assay after HSP90 inhibitor treatment, western blot in cells and clinical specimens\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — co-IP plus kinase activity assay, validated in vivo in clinical samples, single lab\",\n      \"pmids\": [\"20841485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Angiomotin-family proteins AMOT, AMOTL1, and AMOTL2 activate LATS2 through a conserved domain; AMOTL2 serves as a scaffold binding MST2, LATS2, and YAP; LATS2, AMOTL2, and YAP co-localize at tight junctions, suggesting tight junction clustering triggers LATS2 activation at high cell density.\",\n      \"method\": \"Co-immunoprecipitation, kinase activation assay, immunofluorescence for tight junction co-localization\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP showing scaffold complex, activation assay, co-localization, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21832154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LATS2 cooperates with pRB to silence E2F target genes and promote DREAM complex assembly; LATS2 phosphorylates DYRK1A, which in turn phosphorylates the DREAM subunit LIN52; partial LATS2 knockdown suppresses pRB-induced senescence markers.\",\n      \"method\": \"shRNA screen, kinase assay (LATS2 phosphorylating DYRK1A; DYRK1A phosphorylating LIN52), DREAM complex ChIP, gene expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assays plus ChIP plus genetic epistasis via shRNA screen, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21498571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Aurora A phosphorylates Lats2 at Ser380 during mitosis; S380-phosphorylated Lats2 co-localizes at the central spindle with Aurora B; Lats1 phosphorylates Aurora B; the Aurora A-Lats1/2-Aurora B axis regulates accurate mitotic progression; cells expressing non-phosphorylatable S380A Lats2 show chromosome missegregation and cytokinesis failure.\",\n      \"method\": \"In vitro kinase assay, phospho-specific antibody, immunocytochemistry, co-immunoprecipitation, mutant expression analysis\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus phospho-antibody validation plus functional mutant phenotype, single lab\",\n      \"pmids\": [\"21822051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LATS2 is a tumor suppressor in malignant mesothelioma; re-expression of LATS2 in MM cells phosphorylates and inactivates YAP, inhibiting MM cell growth.\",\n      \"method\": \"LATS2 transduction in MM cell lines, western blot for YAP phosphorylation, proliferation assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with defined mechanistic readout (YAP phosphorylation), validated in multiple MM lines and tumors\",\n      \"pmids\": [\"21245096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Lats2 kinase interacts with Snail1 and directly phosphorylates Snail1 at Thr203 in the nucleus, promoting Snail1 nuclear retention and stability, enhancing EMT and tumor cell invasion in a Snail1-dependent manner; during TGFβ-induced EMT, Lats2 is activated and Snail1 is phosphorylated at T203.\",\n      \"method\": \"Live-cell bioluminescence kinome RNAi screen, co-immunoprecipitation, in vitro kinase assay, immunofluorescence, mouse and zebrafish in vivo studies\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with site-specific phosphorylation, validated in multiple model systems (cells, mouse, zebrafish), single lab\",\n      \"pmids\": [\"21952048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LATS2 inhibits oncogenic Wnt/β-catenin transcription by directly interacting with β-catenin and disrupting the β-catenin/BCL9 interaction, independent of LATS2 kinase activity; LATS2 is present on Wnt target gene promoters.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, reporter assay, kinase-dead mutant, in vivo tumor model with nocodazole\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP mapping interaction surface, ChIP on Wnt promoters, kinase-dead mutant defining mechanism, single lab with multiple methods\",\n      \"pmids\": [\"24360964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lats2 phosphorylates p21/CDKN1A at S146 in response to UV irradiation; this phosphorylation is preceded by Chk1-mediated phosphorylation of Lats2 at Ser835 (which activates Lats2 kinase); Lats2-mediated p21 phosphorylation induces p21 degradation, caspase-3 and -9 activation, and apoptosis.\",\n      \"method\": \"In vitro kinase assay, phospho-specific antibodies, overexpression/knockdown, caspase activity assay, western blot\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay identifying substrate and phosphorylation site, validated in vivo with functional apoptosis readout, single lab\",\n      \"pmids\": [\"23886938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"At high cell density, active Lats2 inhibits c-Abl tyrosine kinase activity through direct interaction and phosphorylation of c-Abl, reducing phosphorylation of YAP and p73, and suppressing DNA damage-induced apoptosis; Lats2 knockdown restores c-Abl activity and apoptosis in dense cells.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay for Lats2-c-Abl interaction, phospho-substrate western blot, siRNA knockdown, apoptosis assay\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus co-IP plus functional knockdown phenotype, single lab with multiple methods\",\n      \"pmids\": [\"23852372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LATS2 kinase activation requires phosphorylation of both Ser872 (T-loop) and Thr1041 (hydrophobic motif); MST1/2 phosphorylate LATS2 on Thr1041 but not Ser872; MOB1 binding to LATS2 supports both phosphorylation events; a hyperactive LATS2-PIF variant phosphorylates YAP1 and inhibits its transcriptional co-activity dependent on LATS2 kinase activity but independent of MOB1/LATS2 or YAP1/LATS2 complex formation.\",\n      \"method\": \"Phosphomimetic and phosphoablating LATS2 variants, in vitro kinase assay, MOB1/LATS2 interaction assays, YAP1 transcriptional reporter assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-specific mutagenesis combined with kinase assays and reporter assays, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"26898830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Zyxin acts as a scaffold forming a ternary complex with Lats2 and the E3 ubiquitin ligase Siah2 in response to hypoxia and TGF-β stimuli, facilitating Lats2 ubiquitination and proteasomal degradation, thereby decreasing Hippo signaling and activating YAP.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Lats2 protein stability assay, siRNA knockdown of Zyxin, in vivo xenograft\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ternary complex demonstrated by co-IP, ubiquitination assay establishing mechanism, functional rescue, single lab with multiple methods\",\n      \"pmids\": [\"27030211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Activated YAP, together with TEAD transcription factors, directly induces transcription of LATS2 (but not LATS1), forming an evolutionarily conserved negative feedback loop; this feedback is functionally relevant as Lats2 deletion in a Sav1-knockout mouse liver model severely enhances YAP-induced tumorigenesis.\",\n      \"method\": \"ChIP/reporter assay for YAP-TEAD on LATS2 promoter, Lats2-specific knockout in vivo, soft agar assay, Drosophila ortholog validation\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP/reporter assay plus in vivo genetic model plus cross-species validation (Drosophila), multiple labs implicit via cross-species conservation\",\n      \"pmids\": [\"27006470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LATS2 interacts with the transcription factor SREBP2 (master regulator of cholesterol homeostasis); LATS2 depletion activates SREBP and causes hepatic cholesterol accumulation; liver-specific Lats2 conditional knockout mice develop spontaneous fatty liver disease with constitutive SREBP activation, and show impaired p53 activation and failure to recover from cholesterol-induced damage.\",\n      \"method\": \"Screen for LATS2-interacting proteins, co-immunoprecipitation, liver-specific conditional knockout mouse, western blot, gene expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — protein interaction screen with co-IP validation plus conditional knockout mouse with metabolic phenotypes, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27013235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"JCAD interacts with the kinase domain of LATS2 and inhibits LATS2-mediated phosphorylation of YAP, thereby upregulating CCND1 and GLI2 to promote hepatoma cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, kinase assay (LATS2 phosphorylating YAP in presence/absence of JCAD), western blot, JCAD overexpression/knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — co-IP plus in vitro kinase inhibition assay plus functional overexpression/knockdown, single lab with multiple methods\",\n      \"pmids\": [\"28775168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"USP9X deubiquitylates LATS2 and prevents its proteasomal degradation; anaphase-promoting complex/cyclosome (APC/C) interacts with LATS2 but does not regulate its protein levels or activity; USP9X ablation activates YAP/TAZ and enhances oncogenic potential of pancreatic cancer cells.\",\n      \"method\": \"Tandem affinity purification (TAP), co-immunoprecipitation, ubiquitination assay, USP9X knockdown, protein stability assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — TAP identification followed by co-IP, direct deubiquitination assay, proteasome dependency established, single lab\",\n      \"pmids\": [\"29183995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"YAP1 hyperactivation induces cellular senescence in human ovarian surface epithelial cells; LATS2 is elevated in both YAP1-induced and replicative senescence; deletion of LATS2 in hOSEs prevents senescence and switches YAP-induced senescence to malignant transformation, demonstrating a LATS2-YAP1 negative feedback loop controlling cell fate.\",\n      \"method\": \"LATS2 siRNA/CRISPR deletion, YAP1 overexpression, senescence assays (SA-β-gal), transformation assays in primary hOSEs\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion with defined fate switch phenotype, multiple functional assays, single lab\",\n      \"pmids\": [\"30755404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"O-GlcNAcylation of LATS2 at Thr436 disrupts its interaction with the MOB1 adaptor protein, preventing MST-to-LATS2 signal relay, suppressing LATS2 kinase activity, and consequently hyperactivating YAP/TAZ in breast cancer cells.\",\n      \"method\": \"Mass spectrometry identification of O-GlcNAc site, site-directed mutagenesis (T436A), co-immunoprecipitation of MOB1-LATS2 interaction, YAP/TAZ phosphorylation western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS-identified modification site with mutagenesis validation, co-IP showing disrupted MOB1 binding, functional pathway readout, single lab\",\n      \"pmids\": [\"32513743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LATS2 activates mTORC1 in pancreatic β-cells, suppressing autophagy; LATS2 is itself an autophagy substrate; LATS2 deficiency improves β-cell viability, insulin secretion, and β-cell mass under diabetic conditions; genetic and pharmacological mTORC1 inhibition counteracts LATS2-induced β-cell apoptosis.\",\n      \"method\": \"β-cell-specific Lats2 knockout mice, mTORC1 inhibitor (rapamycin), autophagy flux assay, apoptosis assay, insulin secretion measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional knockout plus pharmacological rescue plus autophagy substrate assay, multiple orthogonal methods\",\n      \"pmids\": [\"34389720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LATS kinases phosphorylate and inhibit MTF1 (metal-responsive transcription factor 1), attenuating heavy metal response gene transcription; this function is independent of YAP/TAZ; zinc directly binds LATS and inhibits its kinase activity following heavy metal treatment.\",\n      \"method\": \"In vitro kinase assay (LATS phosphorylating MTF1), zinc binding to LATS, Hippo-deficient cell lines, transcriptional reporter assay, cell viability under metal stress\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus direct zinc-binding assay plus genetic models, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35027733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LATS2 forms biomolecular condensates in response to F-actin cytoskeleton reduction, mediated by its proline-rich motif (PRM); these condensates assemble a signalosome with core Hippo pathway components, activating LATS2 and protecting it from FBXL16 E3-ligase-dependent degradation; condensation recruits and inactivates YAP/TAZ; the oncogenic FBXL16 complex blocks LATS2 condensation by binding the PRM, promoting LATS2 degradation.\",\n      \"method\": \"Live-cell imaging of condensate formation, PRM deletion/mutation, co-immunoprecipitation of FBXL16-LATS2, ubiquitination assay, LATS2 kinase activity and YAP/TAZ phosphorylation assays, tumor progression models\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — condensate formation with domain-mutant validation, E3 ligase interaction and ubiquitination assay, kinase activation and YAP inactivation readouts, multiple orthogonal methods in single study\",\n      \"pmids\": [\"38200110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Kpm/Lats2 stabilizes YAP2 (through YAP2 phosphorylation at Ser127) and p73 in leukemic cells; Lats2 kinase activity and YAP2 phosphorylation are required for nuclear accumulation of p73, its recruitment to the PUMA promoter, and induction of p21/PUMA expression in response to DNA damage.\",\n      \"method\": \"Co-expression studies, western blot for p73 stability, chromatin immunoprecipitation for p73 at PUMA promoter, Lats2 knockdown/overexpression, kinase-dead mutant\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus kinase-dead mutant analysis plus co-expression, single lab with multiple methods\",\n      \"pmids\": [\"18565851\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LATS2 is a serine/threonine kinase (Dbf2-related/AGC family) that forms the catalytic core of the Hippo tumor-suppressor pathway: it is activated by MST1/2-mediated phosphorylation of its hydrophobic motif (Thr1041) and by MOB1 binding (which also supports T-loop Ser872 phosphorylation), assembles into condensates at the plasma membrane in response to cytoskeletal changes to form a YAP/TAZ-inactivating signalosome, phosphorylates YAP and TAZ to restrict their nuclear activity, and additionally phosphorylates diverse substrates including ASPP1 (promoting p53-dependent apoptosis), Snail1 (nuclear retention for EMT), p21/CDKN1A (promoting degradation and apoptosis after UV), c-Abl (inhibiting DNA-damage apoptosis at high density), DYRK1A (linking to DREAM/pRB senescence), and MTF1 (attenuating heavy metal response); its activity and protein levels are regulated by Aurora A phosphorylation (centrosomal localization), Chk1 phosphorylation (UV response), USP9X deubiquitylation (stabilization), Siah2/Zyxin-mediated ubiquitination (degradation), O-GlcNAcylation at Thr436 (MOB1 uncoupling), HSP90 chaperoning, and transcriptional feedback from YAP-TEAD; it also suppresses Wnt signaling by disrupting β-catenin/BCL9 interaction and inhibits SREBP-driven cholesterol metabolism independently of YAP.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LATS2 is a serine/threonine kinase that functions as the catalytic effector of the Hippo tumor-suppressor pathway and as a broader guardian of genomic integrity and cell-fate control [#1, #17]. Its kinase activity requires dual phosphorylation of the T-loop (Ser872) and the hydrophobic motif (Thr1041), the latter installed by MST1/2, with MOB1 binding supporting both events; this activated kinase phosphorylates and inactivates the transcriptional co-activators YAP/TAZ to restrict their nuclear oncogenic output [#22, #17]. LATS2 activation is spatially organized: angiomotin-family scaffolds (AMOT/AMOTL1/AMOTL2) cluster LATS2 with MST2 and YAP at tight junctions at high cell density [#14], and loss of F-actin drives LATS2 into proline-rich-motif-dependent biomolecular condensates that assemble a Hippo signalosome, activate the kinase, and sequester YAP/TAZ [#32]. Beyond YAP/TAZ, LATS2 directly phosphorylates a diverse substrate set to enforce stress responses and growth arrest: ASPP1 (directing p53 to proapoptotic promoters) [#12], p21/CDKN1A at Ser146 to promote its degradation and UV-induced apoptosis [#20], Snail1 at Thr203 to drive its nuclear retention and EMT [#18], c-Abl to suppress DNA-damage apoptosis at high density [#21], DYRK1A to assemble the DREAM complex and enforce pRB-dependent senescence [#15], and MTF1 to attenuate the heavy-metal response independently of YAP/TAZ [#31]. LATS2 also restrains Wnt signaling kinase-independently by disrupting the \\u03b2-catenin/BCL9 interaction [#19] and limits SREBP-driven hepatic cholesterol metabolism [#25]. The kinase enforces mitotic fidelity through centrosomal and spindle functions, with knockout causing centrosome amplification and cytokinesis failure [#4, #7]. Its abundance and activity are tightly tuned by phosphorylation (Aurora-A, Chk1/Chk2), O-GlcNAcylation at Thr436 (which uncouples MOB1), HSP90 chaperoning, USP9X deubiquitylation, and Siah2/Zyxin- and FBXL16-mediated degradation, as well as a YAP-TEAD transcriptional feedback loop [#2, #10, #29, #13, #27, #23, #32, #24]. Re-expression studies establish LATS2 as a tumor suppressor in malignant mesothelioma and other contexts, frequently silenced by promoter hypermethylation [#17, #9].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the basic identity and chromosomal context of LATS2, placing it at a locus of frequent cancer-associated loss and hinting at a tumor-suppressor role.\",\n      \"evidence\": \"Cell fractionation/immunoblotting and FISH mapping in human cells\",\n      \"pmids\": [\"10673337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional activity demonstrated\", \"Nuclear localization not reconciled with later mitotic/centrosomal findings\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated that LATS2 is a kinase-dependent growth suppressor controlling G1/S transition and tumor formation, defining its core tumor-suppressor function and essential domains.\",\n      \"evidence\": \"Retroviral overexpression in NIH3T3/v-ras, cell cycle profiling, CDK2 kinase assay, domain-deletion mutants, nude mouse tumor assay\",\n      \"pmids\": [\"12853976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates not identified\", \"Mechanism linking kinase activity to cyclin E/CDK2 downregulation unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected LATS2 to mitotic apparatus and centrosome biology, showing it is required for genomic integrity and is regulated by Aurora-A phosphorylation, and that it can trigger intrinsic apoptosis.\",\n      \"evidence\": \"Lats2 knockout mouse and MEFs, Aurora-A in vitro/in vivo phospho-mapping (Ser83), co-IP, immunofluorescence, adenoviral overexpression with apoptosis assays\",\n      \"pmids\": [\"15343267\", \"15147269\", \"15265683\", \"15131260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates at the centrosome not defined\", \"Relationship between AR repression and kinase activity unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified Ajuba as a mitotic LATS2 partner and substrate required for spindle formation, linking LATS2 kinase activity to centrosome maturation.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, siRNA depletion, gamma-tubulin/spindle immunofluorescence\",\n      \"pmids\": [\"16413547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ajuba phosphosite not mapped\", \"Functional consequence of phosphorylation on gamma-tubulin recruitment not dissected\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established that MOB1-family proteins associate with and activate LATS2, and confirmed in vivo essentiality through knockout lethality with mitotic defects.\",\n      \"evidence\": \"Lats2 knockout mouse, MEF phenotyping, Lats2-MOB1 co-IP, immunofluorescence\",\n      \"pmids\": [\"17478426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MOB1-binding interface on LATS2 not mapped here\", \"Mechanism of activation by MOB1 not yet biochemically defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed LATS2 downstream of MST1 in a physiological organ context (heart) and showed it relays growth/apoptosis signals, and linked it to YAP2/p73-dependent DNA-damage gene induction.\",\n      \"evidence\": \"Cardiac transgenic and dominant-negative mice with morphometry; co-expression, p73 stability, PUMA-promoter ChIP, kinase-dead mutant in leukemic cells\",\n      \"pmids\": [\"18927464\", \"18565851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cardiac substrates not identified\", \"Reconciliation of YAP2 stabilization with later YAP-inactivation model not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a stress-checkpoint role in which oncogene-induced ATR-Chk1 signaling relocalizes and stabilizes LATS2 to activate p53, and showed promoter hypermethylation as an escape mechanism.\",\n      \"evidence\": \"Oncogenic H-Ras expression, localization immunofluorescence, qPCR, methylation analysis, death/senescence assays\",\n      \"pmids\": [\"19855428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LATS2 substrate driving p53 activation not pinned down here\", \"Quantitative contribution of methylation in human tumors unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Expanded the LATS2 substrate/regulator network in stress responses (Chk1/Chk2-LATS2-14-3-3\\u03b3 P-body axis, ASPP1-p53 proapoptotic targeting) and identified post-transcriptional control by TTP and chaperoning by HSP90.\",\n      \"evidence\": \"Phosphosite mapping, kinase assays, siRNA, P-body and apoptosis assays; REMSA/luciferase for TTP; co-IP and kinase assay with HSP90 inhibition\",\n      \"pmids\": [\"21118956\", \"21041410\", \"20335167\", \"20841485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy among competing regulatory inputs not established\", \"In vivo relevance of 14-3-3\\u03b3/P-body axis not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Broadened LATS2 substrate scope into senescence (DYRK1A/DREAM), EMT (Snail1 Thr203), and mitotic accuracy (Aurora-A Ser380 axis), and defined density-dependent activation via angiomotins at tight junctions; confirmed tumor suppression via YAP inactivation in mesothelioma.\",\n      \"evidence\": \"shRNA screens, in vitro kinase assays with site mapping, ChIP, phospho-antibodies, mutant phenotyping, co-IP, multi-organism EMT models, MM cell rescue\",\n      \"pmids\": [\"21498571\", \"21952048\", \"21822051\", \"21832154\", \"21245096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single kinase selects among diverse substrates in different contexts unclear\", \"Spatial coordination of mitotic vs Hippo functions unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed kinase-independent (Wnt/\\u03b2-catenin-BCL9) and additional kinase-dependent (p21 Ser146, c-Abl) functions, showing LATS2 integrates UV/DNA-damage and cell-density signals into apoptotic decisions.\",\n      \"evidence\": \"Co-IP, ChIP, kinase-dead and in vitro kinase assays, knockdown, caspase and apoptosis assays, tumor models\",\n      \"pmids\": [\"24360964\", \"23886938\", \"23852372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between proapoptotic and antiapoptotic outputs context-dependence not mechanistically resolved\", \"Structural basis of \\u03b2-catenin/BCL9 disruption unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Resolved the biochemical activation logic (Ser872 + Thr1041, MST1/2, MOB1) and uncovered multiple layers of abundance control (Siah2/Zyxin degradation, YAP-TEAD feedback) plus a YAP-independent metabolic role via SREBP2.\",\n      \"evidence\": \"Phosphomimetic/ablating variants and kinase assays; co-IP and ubiquitination assays; ChIP/reporter and in vivo liver knockouts; interactor screen with conditional knockout metabolic phenotyping\",\n      \"pmids\": [\"26898830\", \"27030211\", \"27006470\", \"27013235\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the active kinase not provided\", \"Crosstalk between metabolic and Hippo outputs not integrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified opposing post-translational regulators of LATS2 stability/activity (JCAD inhibition; USP9X deubiquitylation) that tune YAP/TAZ output in cancer.\",\n      \"evidence\": \"Co-IP, kinase inhibition assays, TAP, ubiquitination and protein-stability assays, knockdown\",\n      \"pmids\": [\"28775168\", \"29183995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase counteracted by USP9X not fully defined here\", \"JCAD-LATS2 binding interface not mapped structurally\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated that the LATS2-YAP1 negative feedback loop acts as a cell-fate switch, with LATS2 enforcing senescence and its loss permitting YAP-driven transformation.\",\n      \"evidence\": \"LATS2 siRNA/CRISPR deletion, YAP1 overexpression, SA-\\u03b2-gal senescence and transformation assays in primary hOSEs\",\n      \"pmids\": [\"30755404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold setting the senescence-vs-transformation switch unknown\", \"Downstream senescence effectors not enumerated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed that O-GlcNAcylation at Thr436 inactivates LATS2 by uncoupling MOB1, providing a metabolic-to-Hippo signaling link that hyperactivates YAP/TAZ.\",\n      \"evidence\": \"Mass spectrometry site ID, T436A mutagenesis, MOB1-LATS2 co-IP, YAP/TAZ phosphorylation western blot in breast cancer cells\",\n      \"pmids\": [\"32513743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"O-GlcNAc transferase responsible not defined here\", \"In vivo contribution to tumorigenesis not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Uncovered a LATS2-mTORC1-autophagy axis in pancreatic \\u03b2-cells, expanding LATS2 function into metabolic-stress-induced apoptosis and revealing it is itself an autophagy substrate.\",\n      \"evidence\": \"\\u03b2-cell-specific Lats2 knockout mice, rapamycin rescue, autophagy flux and apoptosis assays, insulin secretion measurement\",\n      \"pmids\": [\"34389720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mTORC1-pathway substrate of LATS2 not identified\", \"Relationship of this axis to canonical Hippo signaling unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a YAP/TAZ-independent function in which LATS phosphorylates and inhibits MTF1, with zinc directly binding and inhibiting LATS, positioning LATS2 as a sensor in the heavy-metal stress response.\",\n      \"evidence\": \"In vitro kinase assay, zinc-binding assay, Hippo-deficient cells, transcriptional reporters, metal-stress viability assays\",\n      \"pmids\": [\"35027733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MTF1 phosphosite(s) and LATS2-specific contribution vs LATS1 not delineated\", \"Structural basis of zinc inhibition unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the spatial/biophysical basis of LATS2 activation by showing F-actin loss drives PRM-dependent condensation into a Hippo signalosome that activates the kinase, sequesters YAP/TAZ, and is antagonized by FBXL16-mediated degradation.\",\n      \"evidence\": \"Live-cell condensate imaging, PRM mutants, FBXL16-LATS2 co-IP, ubiquitination assay, kinase/YAP-TAZ phosphorylation readouts, tumor models\",\n      \"pmids\": [\"38200110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Condensate composition and material properties not fully characterized\", \"How cytoskeletal sensing is transduced to the PRM unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LATS2 selects among its many substrates and switches between pro- and anti-apoptotic, kinase-dependent and kinase-independent outputs across cellular contexts remains the central open question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No integrated structural model of the active LATS2 kinase with its scaffolds\", \"Quantitative rules governing context-specific substrate choice unknown\", \"In vivo importance of individual non-YAP substrates largely untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 16, 18, 20, 21, 22, 31, 33]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 16, 22, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 26, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 9, 18]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [2, 4, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [14, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 22, 14, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 4, 7, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 12, 20, 21, 33]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 10, 20, 31]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [25, 30]}\n    ],\n    \"complexes\": [\"Hippo signalosome (LATS2 condensate)\", \"DREAM complex (functional link)\"],\n    \"partners\": [\"MOB1\", \"MST1/2\", \"YAP1\", \"AMOTL2\", \"AURKA\", \"USP9X\", \"Zyxin\", \"SREBP2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}